Open Access Pub publishes peer-reviewed, free-to-read open-access articles. Showing
articles matching Bone Mineral Density — open any to read the full text,
or download the PDF or XML.
Aug 2020 DOI 10.14302/issn.2328-0182.japst-20-3447
The cactus Opuntia ficus indica (L.) Mill. (Cactaceae) is widely used in Tunisian medicine for the treatment of various illnesses. The purpose of the present study was to investigate the antioxidant activities of cactus cladode extract (CCE) and to assess the protective effects of Opuntia ficus indica against osteoporosis induced by cadmium chloride in male Wistar rats. Adult male rats were divided into 4 groups of 9 each: a control group, a group injected with cadmium (3.5mg/kg) for 10 weeks, a group orally given a O. ficus indica cladodes aqueous extract (CCE) (100 mg /kg/day) for 10 weeks then treated with cadmium, and a group receiving only (CCE) for 10 weeks. Bone toxicity was estimated by examining femoral length and weight, calcium, phosphorus, alkaline phosphatase (ALP) and total tartrate-resistant acid phosphatase (ACP) levels in serum. Also, bone levels of calcium, phosphorus and vitamin C and bone mineral density (BMD) of femur diaphysis were measured. Alterations of these bone biomarkers and decreased BMD confirmed cadmium-induced bone toxicity. However, when cadmium was administered in rats given CCE, all the biological parameters underwent much less alteration. Administration of CCE was found to be beneficial by attenuating cadmium-induced femur damage. The protective effect of the plant is mainly attributed to its phenolic compounds that orchestrate antioxidant properties, as highlighted by HPLC-based analysis.
The Agency for Toxic Substances and Disease Registry (ATSDR) lists cadmium as one of its priority hazardous substances. The agency conducted a comprehensive literature review of cadmium and used the information to develop a toxicological profile that identified the full range of health effects associated with exposure to cadmium. It included an assessment that identified screening levels, termed health guidance values or minimal risk levels (MRLs), below which adverse health effects are not expected. In this paper, we describe how MRLs for cadmium are derived. For the acute inhalation MRL, the traditional no observed adverse effect level or lowest observed adverse effect level (NOAEL/LOAEL) approach is used; for the oral intermediate MRL, the benchmark dose (BMD) approach is used. MRLs were developed for the most sensitive route-specific end points, other than mortality and cancer that were sufficiently supported and justified by the data. These included an acute duration (1–14 day exposure) inhalation MRL of 0.03 µg Cd/m3 for alveolar histiocytic infiltration and focal inflammation in alveolar septa and an intermediate duration (15–365 day exposure) oral MRL of 0.5 µg Cd/kg/day for decreased bone mineral density